Teacher Retirement System of Texas Sells 13,827 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Teacher Retirement System of Texas cut its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 38.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,568 shares of the medical equipment provider's stock after selling 13,827 shares during the period. Teacher Retirement System of Texas' holdings in Lantheus were worth $2,019,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Xponance Inc. lifted its holdings in shares of Lantheus by 4.6% during the fourth quarter. Xponance Inc. now owns 9,786 shares of the medical equipment provider's stock valued at $875,000 after purchasing an additional 427 shares during the last quarter. Boston Partners raised its holdings in shares of Lantheus by 57.5% during the fourth quarter. Boston Partners now owns 400,797 shares of the medical equipment provider's stock valued at $36,201,000 after acquiring an additional 146,268 shares during the period. William Blair Investment Management LLC lifted its position in shares of Lantheus by 2.5% in the 4th quarter. William Blair Investment Management LLC now owns 380,324 shares of the medical equipment provider's stock valued at $34,024,000 after acquiring an additional 9,245 shares in the last quarter. Cibc World Markets Corp acquired a new position in Lantheus in the 4th quarter worth approximately $576,000. Finally, First National Advisers LLC grew its position in Lantheus by 4.1% during the 4th quarter. First National Advisers LLC now owns 27,914 shares of the medical equipment provider's stock worth $2,497,000 after purchasing an additional 1,098 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on LNTH. The Goldman Sachs Group started coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price objective for the company. Truist Financial upped their price target on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. B. Riley dropped their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Lantheus has an average rating of "Moderate Buy" and a consensus price target of $129.43.

Lantheus Stock Up 1.5 %

LNTH stock traded up $1.44 during midday trading on Monday, reaching $97.60. 1,052,632 shares of the company's stock traded hands, compared to its average volume of 942,562. The firm's fifty day moving average price is $93.34 and its 200-day moving average price is $96.34. The company has a market cap of $6.68 billion, a price-to-earnings ratio of 16.24 and a beta of 0.38. Lantheus Holdings, Inc. has a 52 week low of $58.16 and a 52 week high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Activity

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at $11,445,207.20. This trade represents a 8.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 64,109 shares of company stock worth $6,110,806 in the last three months. Corporate insiders own 1.50% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.